adrenocortical steroids due to a dysfunctional hypothalamic-pituitaryadrenocortical (HPA) axis.METHODS: We evaluated the pre-(VB2) and post-prostatic massage (VB3) urine levels of several novel biomarkers of dysfunctional HPA axis activity.VB2 and VB3 samples were collected from 24 men with a diagnosis of CP/CPPS (median age, 48 years) and 30 age-matched asymptomatic controls.Patients and controls underwent standardized clinical evaluation and were required to complete the National Institutes Chronic Prostatitis Symptom Index (NIH-CPSI).The following biomarkers were measured in VB2 and VB3 using ELISA kits: corticotropin releasing hormone (CRH), neuropeptide Y (NPY), both obtained from Phoenix Pharmaceuticals, Belmont, CA), dehydroepiandrosterone (DHEA) and epidermal growth factor (EGF) from R & D Systems, Minneapolis, MN.Galanin levels were measured using RIA (Phoenix Pharmaceuticals, Belmont, CA).Modified allostatic load score was calculated based on a review of the neuroscientific literature.RESULTS: Allostatic load scores were significantly higher in patients with CPPS as compared with controls (P<0.001).Furthermore, PPMU NPY and galanin levels in CPPS patients were significantly lower as compared to those in controls.The PPMU of CRH and DHEA were significantly higher as compared with controls (P<0.001).CONCLUSIONS: Our results show evidence of allostatic overload in CPPS patients as compared with controls and provide exciting insights into possible therapeutic avenues for the management of CPPS based on allostatic scores.

95: A Preliminary Analysis of Calcifying Particles in the Serum and Prostates of Patients with Prostatic Inflammation